Pharmacokinetics of phenytoin in hyperlipidemia

European Journal of Pharmaceutical Sciences

Volumn 4, Issue 1, 1996, Pages 33-37

  Dutkiewicz, Grazyna ^a   Wójcicki, Jerzy ^a   Gawrońska Szklarz, Barbara ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

Hyperlipidemia; Pharmacokinetics; Phenytoin

Indexed keywords

PHENYTOIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0343338079     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/0928-0987(95)00024-0     Document Type: Review

References (18)

1. Aleksandrow, D., Michajlik, A., Bartnikowska, A. (1975) Blood lipids in neonates and mothers-attempted early diagnosis of primary hyperlipidemias. Pol. Tyg. Lek. 30, 5-8 (in Polish).
2. Baird-Lambart, J., Manglick, M.P., Walle, N., Buchanan, N. (1987) Identifying patients who might benefit from free phenytoin monitoring. Ther. Drug Monit. 9, 134-138.
3. Bernstein, H., Gold, H., Lang, T., Pappelbaum, S., Bazika, V., Corday, E. (1965) Sodium diphenylhydantoin in the treatment of recurrent cardiac arrhythmias. J. Am. Med. Assoc. 191, 696-699.
4. Bochner, F., Hooper, W.D., Sutherland. J.N., Eadie, M.J., Tyler, J.H. (1973) The renal handling of diphenylhydantoin and 5-p-hydroxyphenyl-5-phenylhydation. Clin. Pharmacol. Ther. 14, 791-796.
5. Bowdle, T.A., Patel, I.H., Levy, R.H., Wilensky, A.J. (1983) The influence of free fatty acid plasma protein binding during fasting in normal humans. Eur. J. Pharmacol. 23, 343-347.
6. Cenedella, R.J., Crouthamel, W.G., Bierkamper, G.C., Westfall, D.D. (1975) Alteration of drug pharmacokinetics by hyperlipidemia. Arch. Int. Pharmacodyn. Ther. 218, 299-311.
7. Dehorgeril, M., Boissonnat, P., Bizollon, C.A., Guidollet, J., Faucon, G., Guichard, J.P., Levy-Prades-Sauron, R., Renoued, S., Dureau, G. (1992) Pharmacokinetics of cyclosporine in hyperlipidemic long-term survivors of heart transplantation. Eur. J. Clin. Pharmacol. 43, 161-165.
8. Dutkiewicz, G., Wójcicki, J., Gawrońska-Szklarz, B. (1994) Effect of hyperlipidemia on pharmacokinetics of free phenytoin. Neur. Neurochir. Pol. 28, 845-852 (in Polish).
9. Gibaldi, M., Perrier, D. (1982) Pharmacokinetics. Marcel Dekker, New York.
10. Goodman, L.S., Gilman, A. (1990) The Pharmacological Basis of Therapeutics, 8th edition. Macmillan, New York.
11. Jusko, W.P., Koupr, J.R., Alvan, G. (1976) Nonlinear assessment of phenytoin bioavailability. J. Pharmacokinet. Biopharm. 4, 327-336.
12. Krieglstein, J., Meffert, A., Niemeyer, D. (1984) Influence of emulsified fat on chlorpromazine availability in rabbit blood. Experientia 30, 924-928.
13. Oder-Cederlock, J., Boys, O. (1976) Impaired plasma protein binding of phenytoin in uremia displacement of salicylic acid. Clin. Pharmacol. Ther. 20, 36-47.
14. Straathof, P., Vermeij, T.A.C. (1984) Influence of intralipid infusion on the elimination of phenytoin. Arch. Int. Pharmacodyn. 267, 180-186.
15. Wagner, J.G. (1975) Fundamentals of Clinical Pharmacokinetics. Drug Intelligence Publications, Hamilton, Ont., Canada.
16. Wichliński, L., Sieradzki, E. (1984) Comparative studies of the influence of elevated serum lipid levels on the pharmacokinetics of diazepam in rabbits and humans. Drug Intel. Clin. Pharmacol. 14, 765-768.
17. Wing, D.S., Duff, H.J. (1989) The impact of a therapeutic drug monitoring program for phenytoin. Ther. Drug Monit. 11, 32-37.
18. Wójcicki, J., Kalinowski, W., Gawrońska-Szklarz, B. (1985) Comparative pharmacokinetics of doxycycline and oxytetracycline in patients with hyperlipidemia. Arzneim. Forsch. 35, 991-993.